|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen WQ, Zheng RS, Zhang SW, Zeng HM and
Zou XN: The incidences and mortalities of major cancers in China,
2010. Chin J Cancer. 33:402–405. 2014.PubMed/NCBI
|
|
3
|
Lin Y, Totsuka Y, He Y, Kikuchi S, Qiao Y,
Ueda J, Wei W, Inoue M and Tanaka H: Epidemiology of esophageal
cancer in Japan and China. J Epidemiol. 23:233–242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsushima K, Isomoto H, Kohno S and Nakao
K: MicroRNAs and esophageal squamous cell carcinoma. Digestion.
82:138–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kruger JM, Fukushima T, Cherepanov V,
Borregaard N, Loeve C, Shek C, Sharma K, Tanswell AK, Chow CW and
Downey GP: Protein-tyrosine phosphatase MEG2 is expressed by human
neutrophils. Localization to the phagosome and activation by
polyphosphoinositides. J Biol Chem. 277:2620–2628. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu MJ, Sui X, Zhao R, Dai C, Krantz SB and
Zhao ZJ: PTP-MEG2 is activated in polycythemia vera erythroid
progenitor cells and is required for growth and expansion of
erythroid cells. Blood. 102:4354–4360. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huynh H, Wang X, Li W, Bottini N, Williams
S, Nika K, Ishihara H, Godzik A and Mustelin T: Homotypic secretory
vesicle fusion induced by the protein tyrosine phosphatase MEG2
depends on polyphosphoinositides in T cells. J Immunol.
171:6661–6671. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Krugmann S, Anderson KE, Ridley SH, Risso
N, McGregor A, Coadwell J, Davidson K, Eguinoa A, Ellson CD, Lipp
P, et al: Identification of ARAP3, a novel PI3K effector regulating
both Arf and Rho GTPases, by selective capture on phosphoinositide
affinity matrices. Mol Cell. 9:95–108. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang D, Marlin MC, Liang Z, Ahmad M,
Ashpole NM, Sonntag WE, Zhao ZJ and Li G: The protein tyrosine
phosphatase MEG2 regulates the transport and signal transduction of
tropomyosin receptor kinase A. J Biol Chem. 291:23895–23905. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huynh H, Bottini N, Williams S, Cherepanov
V, Musumeci L, Saito K, Bruckner S, Vachon E, Wang X, Kruger J, et
al: Control of vesicle fusion by a tyrosine phosphatase. Nat Cell
Biol. 6:831–839. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cho CY, Koo SH, Wang Y, Callaway S,
Hedrick S, Mak PA, Orth AP, Peters EC, Saez E, Montminy M, et al:
Identification of the tyrosine phosphatase PTP-MEG2 as an
antagonist of hepatic insulin signaling. Cell Metab. 3:367–378.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang S, Liu S, Tao R, Wei D, Chen L, Shen
W, Yu ZH, Wang L, Jones DR, Dong XC and Zhang ZY: A highly
selective and potent PTP-MEG2 inhibitor with therapeutic potential
for type 2 diabetes. J Am Chem Soc. 134:18116–18124. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan T, Wang Y, Zhao ZJ and Gu H:
Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and
epidermal growth factor receptor signaling in breast cancer cells.
J Biol Chem. 285:14861–14870. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Su F, Ren F, Rong Y, Wang Y, Geng Y, Wang
Y, Feng M, Ju Y, Li Y, Zhao ZJ, et al: Protein tyrosine phosphatase
Meg2 dephosphorylates signal transducer and activator of
transcription 3 and suppresses tumor growth in breast cancer.
Breast Cancer Res. 14:R382012. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du WW, Fang L, Li M, Yang X, Liang Y, Peng
C, Qian W, O'Malley YQ, Askeland RW, Sugg SL, et al: MicroRNA
miR-24 enhances tumor invasion and metastasis by targeting PTPN9
and PTPRF to promote EGF signaling. J Cell Sci. 126:1440–1453.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hao Q, Samten B, Ji HL, Zhao ZJ and Tang
H: Tyrosine phosphatase PTP-MEG2 negatively regulates vascular
endothelial growth factor receptor signaling and function in
endothelial cells. Am J Physiol Cell Physiol. 303:C548–C553. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hromadnikova I, Kotlabova K, Hympanova L
and Krofta L: Gestational hypertension, preeclampsia and
intrauterine growth restriction induce dysregulation of
cardiovascular and cerebrovascular disease associated microRNAs in
maternal whole peripheral blood. Thromb Res. 137:126–140. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu L, Li H, Chen L, Ma X, Gao Y, Li X,
Zhang Y, Fan Y and Zhang X: MicroRNAs as prognostic molecular
signatures in renal cell carcinoma: A systematic review and
meta-analysis. Oncotarget. 6:32545–32560. 2015.PubMed/NCBI
|
|
19
|
Meister J and Schmidt MH: miR-126 and
miR-126*New players in cancer. ScientificWorldJournal.
10:2090–2100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shang AQ, Xie YN, Wang J, Sun L, Wei J, Lu
WY, Lan JY, Wang WW, Wang L and Wang LL: Predicative values of
serum microRNA-22 and microRNA-126 levels for non-small cell lung
cancer development and metastasis: A case-control study. Neoplasma.
64:2017.(Epub ahead of print). View Article : Google Scholar
|
|
21
|
Yuan W, Guo YQ, Li XY, Deng MZ, Shen ZH,
Bo CB, Dai YF, Huang MY, Yang ZY, Quan YS, et al: MicroRNA-126
inhibits colon cancer cell proliferation and invasion by targeting
the chemokine (C-X-C motif) receptor 4 and Ras homolog gene family,
member A, signaling pathway. Oncotarget. 7:60230–60244.
2016.PubMed/NCBI
|
|
22
|
Wang CZ, Yuan P and Li Y: MiR-126
regulated breast cancer cell invasion by targeting ADAM9. Int J
Clin Exp Pathol. 8:6547–6553. 2015.PubMed/NCBI
|
|
23
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-126 inhibits proliferation, migration, invasion and EMT in
osteosarcoma by targeting ZEB1. J Cell Biochem. 2017.(Epub ahead of
print). View Article : Google Scholar
|
|
24
|
Wang J, Zhou Y, Fei X, Chen X, Yan J, Liu
B and Zhu Z: ADAM9 functions as a promoter of gastric cancer growth
which is negatively and post-transcriptionally regulated by
miR-126. Oncol Rep. 37:2033–2040. 2017.PubMed/NCBI
|
|
25
|
Zhu X, Li H, Long L, Hui L, Chen H, Wang
X, Shen H and Xu W: miR-126 enhances the sensitivity of non-small
cell lung cancer cells to anticancer agents by targeting vascular
endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai).
44:519–526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Png KJ, Halberg N, Yoshida M and Tavazoie
SF: A microRNA regulon that mediates endothelial recruitment and
metastasis by cancer cells. Nature. 481:190–194. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Z, Li N, Wu M, Li X, Luo Z and Wang X:
Expression of miR-126 suppresses migration and invasion of colon
cancer cells by targeting CXCR4. Mol Cell Biochem. 381:233–242.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yue S, Shi H, Han J, Zhang T, Zhu W and
Zhang D: Prognostic value of microRNA-126 and CRK expression in
gastric cancer. Onco Targets Ther. 9:6127–6135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Huang X, Gschweng E, van Handel B, Cheng
D, Mikkola HK and Witte ON: Regulated expression of
microRNAs-126/126* inhibits erythropoiesis from human embryonic
stem cells. Blood. 117:2157–2165. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wittekind C: 2010 TNM system: On the 7th
edition of TNM classification of malignant tumors. Pathologe.
31:331–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li H, Meng F, Ma J, Yu Y, Hua X, Qin J and
Li Y: Insulin receptor substrate-1 and Golgi phosphoprotein 3 are
downstream targets of miR126 in esophageal squamous cell carcinoma.
Oncol Rep. 32:1225–1233. 2014.PubMed/NCBI
|
|
33
|
Arnal MJ Domper, Ferrández Arenas Á and
Lanas Arbeloa Á: Esophageal cancer: Risk factors, screening and
endoscopic treatment in Western and Eastern countries. World J
Gastroenterol. 21:7933–7943. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hu B, Yan X, Liu F, Zhu C, Zhou H, Chen Y,
Liu J, Gu X, Ni R and Zhang T: Downregulated expression of PTPN9
contributes to human hepatocellular carcinoma growth and
progression. Pathol Oncol Res. 22:555–565. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hong Y, Liang H, Uzair-Ur-Rehman, Wang Y,
Zhang W, Zhou Y, Chen S, Yu M, Cui S, Liu M, et al: miR-96 promotes
cell proliferation, migration and invasion by targeting PTPN9 in
breast cancer. Sci Rep. 6:374212016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nie ZC, Weng WH, Shang YS, Long Y, Li J,
Xu YT and Li Z: MicroRNA-126 is down-regulated in human esophageal
squamous cell carcinoma and inhibits the proliferation and
migration in EC109 cell via PI3K/AKT signaling pathway. Int J Clin
Exp Pathol. 8:4745–4754. 2015.PubMed/NCBI
|
|
38
|
Liu R, Gu J, Jiang P, Zheng Y, Liu X,
Jiang X, Huang E, Xiong S, Xu F, Liu G, et al: DNMT1-microRNA126
epigenetic circuit contributes to esophageal squamous cell
carcinoma growth via ADAM9-EGFR-AKT signaling. Clin Cancer Res.
21:854–863. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ,
Wang TY, Li HC and Wu XN: Differential expression of miRNAs in
esophageal cancer tissue. Oncol Lett. 5:1639–1642. 2013.PubMed/NCBI
|
